Frederick Finnegan - Mar 16, 2022 Form 4 Insider Report for SAB Biotherapeutics, Inc. (SABS)

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	SABS	Employee Stock Option (right to buy)	Award	$0	+23.5K		$0.00	23.5K	Mar 16, 2022	Common Stock	23.5K	$1.78	Direct	F1, F2

Showing 1 to 1 of 1 entries

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Id	Content
F1	Represents options to purchase shares of common stock pursuant to the Company's 2021 Omnibus Equity Incentive Plan.
F2	The shares underlying the option will vest in full on the one-year anniversary of March 16, 2022, the date the award was approved by the Company's board of directors.